20.36

0.59% -0.12

Bicycle Therapeutics Plc Adr (BCYC)

Overview News Price History Option Chain Financials Discussions Forecast

Bicycle Therapeutics Plc Adr stock is traded at $20.36, with a volume of 268.24K. It is down -0.59% in the last 24 hours and down -24.68% over the past month. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Previous Close:

$20.48

Open:

$20.49

24h Volume:

268.24K

Relative Volume:

0.93

Market Cap:

$1.40B

Revenue:

$26.98M

Net Income/Loss:

$-180.66M

P/E Ratio:

-4.3504

EPS:

-4.68

Net Cash Flow:

$-63.56M

1W Performance:

-12.32%

1M Performance:

-24.68%

6M Performance:

-6.22%

1Y Performance:

+49.38%

1-Day Range:

$20.15

$20.90

1-Week Range:

$19.95

$23.50

52-Week Range:

$13.07

$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name

Bicycle Therapeutics Plc Adr

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

011441223261503

Address

BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE

Employee

284

Twitter

@Bicycle_tx

Next Earnings Date

2024-10-31

Latest SEC Filings

BCYC's Discussions on Twitter

Compare BCYC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCYC	20.36	1.40B	26.98M	-180.66M	-63.56M	-4.68
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight
Jul-06-22	Resumed	Canaccord Genuity	Buy
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight
Dec-17-21	Initiated	SVB Leerink	Outperform
Dec-09-21	Initiated	Needham	Buy
Sep-30-21	Initiated	B. Riley Securities	Buy
Apr-20-21	Initiated	JMP Securities	Mkt Outperform
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy
Nov-14-19	Initiated	ROTH Capital	Buy
Sep-11-19	Upgrade	Goldman	Neutral → Buy
Jun-17-19	Initiated	Canaccord Genuity	Buy
Jun-17-19	Initiated	Goldman	Neutral
Jun-17-19	Initiated	Jefferies	Buy
Jun-17-19	Initiated	Piper Jaffray	Overweight

View All

Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News

Nov 13, 2024

Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India

Nov 13, 2024

Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com

Nov 13, 2024

Oct 28, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India

Oct 28, 2024

Oct 23, 2024

Bicycle Therapeutics spotlights cancer treatment targets - Investing.com

Oct 23, 2024

Oct 19, 2024

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN

Oct 19, 2024

Oct 14, 2024

A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily

Oct 14, 2024

Oct 10, 2024

BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 10, 2024

Oct 08, 2024

Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily

Oct 08, 2024